LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial. (nature.com)

Authors: Mabrouk OS … Graham DL Journal: Nature Medicine Published: 2026-04-01 DOI: https://doi.org/10.1038/s41591-026-04262-4